CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on clinical research to evaluate the effectiveness of SEN0014196, a novel treatment for Huntington’s Disease. It aims to establish pharmacodynamic readouts to demonstrate the compound's potential in modifying the disease's progression.
The Consortium will undertake clinical research activities aimed at ascertaining feasibility of a range of pharmacodynamic readouts for use in the clinical development of SEN0014196 to demonstrate the disease-modifying properties of the compound in Huntington’s Disease.
SEN0014196 is a novel and selective SirT1 inhibitor, currently in Phase I clinical development, and enjoys Orphan Status in the EU as of September 2, 2009.
A multi-factorial approach will be used, including assessment of both nov…
SIENA BIOTECH SPA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Ulm
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
LONDON
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Poland, WARSZAWA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 sectors.
